Jeffrey T L Smith Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jeffrey Smith ZYME stock SEC Form 4 insiders trading

Jeffrey has made over 29 trades of the Zymeworks BC Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Jeffrey exercised 32,728 units of ZYME stock worth $135,821 on 16 September 2019.

The largest trade Jeffrey's ever made was exercising 61,818 units of Zymeworks BC Inc stock on 21 May 2015 worth over $3,709. On average, Jeffrey trades about 6,674 units every 45 days since 2014. As of 16 September 2019 Jeffrey still owns at least 38,000 units of Zymeworks BC Inc stock.

You can see the complete history of Jeffrey Smith stock trades at the bottom of the page.

What's Jeffrey Smith's mailing address?

Jeffrey's mailing address filed with the SEC is C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709.

Insiders trading at Zymeworks BC Inc

Over the last 6 years, insiders at Zymeworks BC Inc have traded over $15,586,802 worth of Zymeworks BC Inc stock and bought 5,881,975 units worth $49,789,204 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Capital, Llc Eco R1 oraz Group, Llc Green Jeremy Red.... On average, Zymeworks BC Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,629,555. The most recent stock trade was executed by Kenneth Galbraith on 5 January 2024, trading 47,666 units of ZYME stock currently worth $576,759.

What does Zymeworks BC Inc do?

zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.

Zymeworks BC Inc executives and stock owners

Zymeworks BC Inc executives and other stock owners filed with the SEC include:

• Dr. Ali Tehrani,
  Co-Founder, Pres, CEO & Director
• Dr. Anthony J. Polverino Ph.D.,
  Chief Scientific Officer & Exec. VP of Early Devel.
• Neil A. Klompas C.A., CPA, CPA, CA,
  Exec. VP of Bus. Operations & CFO
• Kathryn O'Driscoll,
  Chief People Officer
• Wajida Leclerc,
  VP of HR
• Dr. Jennifer Kaufman-Shaw L.L.B., LLB, Ph.D.,
  VP of Intellectual Property
• Dr. David Poon Ph.D.,
  VP of Bus. Devel. and Alliance Management
• James Daniel Guylain Priour,
  Chief Commercial Officer
• Dr. Neil Josephson M.D.,
  Chief Medical Officer
• Daniel Dex,
  VP of Legal & Corp. Sec.
• Neil Gallagher,
  
• Jeffrey T L Smith,
  EVP & Chief Medical Officer
• Kenneth Galbraith,
  Chair & CEO
• James Priour,
  Chief Commercial Officer
• Carlos Campoy,
  
• Lilly & Co Eli,
  10% owner
• Alessandra Cesano,
  
• Ali Tehrani,
  Chief Executive Officer
• David Kai Yuen Poon,
  See Remarks
• Diana Hausman,
  Chief Medical Officer
• Anthony J. Polverino,
  Chief Scientific Officer
• Nick Bedford,
  Director
• Natalie Sacks,
  Director
• Kenneth J. Hillan,
  
• Lota S. Zoth,
  Director
• Leone D Patterson,
  EVP, Chief Bus & Fin Officer
• Capital, Llc Eco R1,
  10% owner
• Bros. Advisors Lp667, L.P.B...,
  
• Paul Andrew Moore,
  Chief Scientific Officer
• Christopher Astle,
  SVP & Chief Financial Officer
• Neil A Klompas,
  President & COO
• Neil Josephson,
  Chief Medical Officer
• Group, Llc Green Jeremy Red...,
  
• Nancy Davidson,
  
• Susan Mahony,
  
• Hollings Renton,
  
• Derek John Michael Miller,
  
• Troy Cox,
  
• Kelvin Neu,